Dr. Garon on Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD
Published: Thursday, Aug 31, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x